牛牛AI助理已提取核心訊息
On December 31, 2023, Altimmune Inc. was the subject of a Schedule 13G filing with the United States Securities and Exchange Commission (SEC), indicating a change in ownership by certain entities and individuals. The filing was made under Rule 13d-1(c), which is used for persons who have acquired beneficial ownership of more than 5% of a class of equity securities of a public company. The entities and individuals listed in the filing include Avidity Partners Management LP, Avidity Partners Management (GP) LLC, Avidity Capital Partners Fund (GP) LP, Avidity Capital Partners (GP) LLC, Avidity Master Fund LP, David Witzke, and Michael Gregory. All parties reported owning 0 shares and thus, 0.0% of the class of common stock of Altimmune Inc. The filing also indicated that as...Show More
On December 31, 2023, Altimmune Inc. was the subject of a Schedule 13G filing with the United States Securities and Exchange Commission (SEC), indicating a change in ownership by certain entities and individuals. The filing was made under Rule 13d-1(c), which is used for persons who have acquired beneficial ownership of more than 5% of a class of equity securities of a public company. The entities and individuals listed in the filing include Avidity Partners Management LP, Avidity Partners Management (GP) LLC, Avidity Capital Partners Fund (GP) LP, Avidity Capital Partners (GP) LLC, Avidity Master Fund LP, David Witzke, and Michael Gregory. All parties reported owning 0 shares and thus, 0.0% of the class of common stock of Altimmune Inc. The filing also indicated that as of the date of the filing, the reporting persons have ceased to be the beneficial owner of more than five percent of the class of securities. The principal business address for the entities and individuals is located in Dallas, Texas, with the exception of Avidity Master Fund LP, which is based in the Cayman Islands. The filing includes a certification that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
2023年12月31日，Altimmune Inc.成爲向美國證券交易委員會（SEC）提交的附表13G文件的主體，該文件表明某些實體和個人的所有權發生了變化。該申請是根據第13d-1（c）條提交的，該規則適用於已獲得上市公司某類股權證券5％以上的受益所有權的人。文件中列出的實體和個人包括Avidity Partners Management LP、Avidity Partners Management（GP）有限責任公司、Avidity Capital Partners（GP）有限責任公司、Avidity Master Fund LP、David Witzke和Michael Gregory。...展開全部
2023年12月31日，Altimmune Inc.成爲向美國證券交易委員會（SEC）提交的附表13G文件的主體，該文件表明某些實體和個人的所有權發生了變化。該申請是根據第13d-1（c）條提交的，該規則適用於已獲得上市公司某類股權證券5％以上的受益所有權的人。文件中列出的實體和個人包括Avidity Partners Management LP、Avidity Partners Management（GP）有限責任公司、Avidity Capital Partners（GP）有限責任公司、Avidity Master Fund LP、David Witzke和Michael Gregory。所有各方均報告擁有0股股份，因此佔Altimmune Inc.普通股類別的0.0％。該文件還顯示，截至申報之日，申報人已不再是該類別超過5％的證券的受益所有人。除總部設在開曼群島的Avidity Master Fund LP外，這些實體和個人的主要營業地址位於德克薩斯州的達拉斯。該文件包括一份證明，證明這些證券是在正常業務過程中收購的，不是爲了改變或影響發行人的控制權。
有用
沒用